Gosuranemab (powder)
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1788032-39-2
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Gosuranemab (powder) exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:rTg4510[1]
-
Dosage:murine version IPN002
-
Administration:weekly; 8 weeks
-
Result:Reduced levels of unbound tau in cerebrospinal fluid (CSF) and interstitial fluid (ISF) at 57 days post-treatment initiation.
-
IgG4-kappa
Chemical Information
-
CAS No. 1788032-39-2
-
Synonyms
BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457. [Content Brief]
[2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gosuranemab (powder) Related Classifications
HY-P99648A Related Classifications
Powered by Bioz
- Gosuranemab (powder)
- 1788032-39-2
- BMS-986168 (powder)
- IPN007 (powder)
- BIIB092 (powder)
- Tau Protein
- AD brain homogenates
- total tau
- extracellular N-terminal tau
- rTg4510 tauopathy transgenic mice
- phosphorylated tau181
- Alzheimer’s disease
- progressive supranuclear palsy
- tau PET SUVR
- blood-brain barrier
- cerebrospinal fluid
- Inhibitor
- inhibitor
- inhibit